GAMA/WiggleZ: The 1.4GHz radio luminosity functions of high- and low-excitation radio galaxies and their redshift evolution to z=0.75 by Pracy, M, Ching, J, Sadler, E, Croom, S, Baldry, I, Bland-Hawthorn, J, Brough, S, Brown, M, Couch, W, Davis, T, Drinkwater, M, Jarvis, M, Jelliffe, B, Jurek, R, Loveday, J, Pimbblet, K, Prescott, M, Wisnioski, E, Woods, D

“…The radio AGN are separated into low-excitation radio galaxies (LERGs) and high-excitation radio galaxies (HERGs) using the optical spectra. We derive radio luminosity functions for LERGs and HERGs separately in the three redshift bins (0.005 < z < 0.3, 0.3 < z < 0.5 and 0.5 < z < 0.75). …”

Galaxy And Mass Assembly (GAMA): The environments of high- and low-excitation radio galaxies by Ching, J, Croom, S, Sadler, E, Robotham, A, Brough, S, Baldry, I, Bland-Hawthorn, J, Colless, M, Driver, S, Holwerda, B, Hopkins, A, Jarvis, M, Johnston, H, Kelvin, L, Liske, J, Loveday, J, Norberg, P, Pracy, M, Steele, O, Thomas, D, Wang, L

“…We find that LERGs and HERGs exist in different environments and that this difference is dependent on radio luminosity. …”

Prediction of Thorough QT study results using action potential simulations based on ion channel screens by Mirams, G, Davies, M, Brough, S, Bridgland−Taylor, M, Cui, Y, Gavaghan, D, Abi−Gerges, N

“…Methods: Ion current reduction was measured, in the presence of marketed drugs which have had a TQT study, for channels encoded by hERG, CaV1.2, NaV1.5, KCNQ1/MinK, and Kv4.3/KChIP2.2. …”

Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment by Elkins, R, Davies, MR, Brough, S, Gavaghan, D, Cui, Y, Abi-Gerges, N, Mirams, G

“…Methods: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro™ screens when detecting block of IKr (hERG), INa (NaV1.5), ICaL (CaV1.2), IKs (KCNQ1/minK) and Ito (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for ICaL (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. …”

Variability in high−throughput ion channel screening data and consequences for cardiac safety assessment by Elkins, R, Davies, M, Brough, S, Gavaghan, D, Cui, Y, Abi−Gerges, N, Mirams, G

“…Methods: we quantified the variability associat11 ed with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks® Quattro— screens when detecting block of IKr (hERG), INa (NaV1.5), ICaL (CaV1.2), IKs (KCNQ1/minK) and Ito Kv4.3/KChIP2.2), and the Molecular Devices FLIPR® Tetra fluorescence screen for ICaL (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. …”